• In February 2026, Hims & Hers Health and Novo Nordisk entered into a partnership allowing Hims to offer branded obesity drugs like Wegovy and Ozempic through its telehealth platform, resolving their earlier legal dispute over compounded semaglutide products.
• This agreement reshapes Hims & Hers Health’s weight-loss offering by shifting from compounded alternatives to branded therapies, potentially reducing legal overhang while introducing new supply and regulatory dependencies.
• Next, we’ll examine how this branded-GLP-1 partnership with Novo Nordisk may alter Hims & Hers Health’s previously outlined investment narrative.

Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

Hims & Hers Health Investment Narrative Recap

To own Hims & Hers Health, you need to believe in its ability to turn a broad, consumer-facing telehealth platform into durable, recurring health relationships. The Novo Nordisk partnership directly reshapes the key short term catalyst around GLP-1 weight loss by moving from compounded to branded drugs, while the biggest current risk remains regulatory and supply exposure tied to obesity medications, rather than international expansion or new categories.

The most relevant recent announcement is the 2025 earnings release and 2026 revenue guidance, with management guiding to US$2.7–2.9 billion in sales. That outlook was set before the branded GLP-1 deal and was based on a mix of weight loss, sexual health, and newer offerings like lab testing and cancer screening. How the Novo Nordisk agreement interacts with that guidance now sits at the center of the near term catalyst story.

Yet, behind the optimism around GLP-1 access, the heightened scrutiny on compounded and telehealth weight loss treatments is something investors should be aware of as...

Hims & Hers Health's narrative projects $3.3 billion revenue and $261.3 million earnings by 2028. This requires 18.3% yearly revenue growth and an earnings increase of about $67.7 million from $193.6 million today.

Uncover how Hims & Hers Health's forecasts yield a $44.36 fair value, a 182% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Hims could reach about US$4.1 billion in revenue and US$331.6 million in earnings, but when you weigh that against rising regulatory risk around lifestyle medications, it shows how widely views can differ and why it is worth exploring more than one possible path from here.

Explore 59 other fair value estimates on Hims & Hers Health - why the stock might be worth over 10x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The future of work is here. Discover the 28 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.